PUT - SPRINTER OPEN END - BIOGEN IDEC | Delayed Deutsche Boerse AG 19:01:21 15/05/2024 BST | ||
| 10.47 EUR | -9.19% |
|
| Current month | -7.69% | ||
| 1 month | -17.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 15/05/24 | 10.47 | -9.19% |
| 14/05/24 | 11.53 | -0.86% |
| 13/05/24 | 11.63 | -1.77% |
| 10/05/24 | 11.84 | -0.84% |
| 09/05/24 | 11.94 | -0.67% |
Delayed Quote Deutsche Boerse AG
Last update May 15, 2024 at 07:01 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VV7EKC |
| ISIN | DE000VV7EKC9 |
| Date issued | 29/09/2022 |
| Strike | 347.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 7.62 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.9 € |
|---|---|
| Lowest since issue | 2.35 € |
| Spread | 0.03 € |
| Spread % | 0.29% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
226.9
USD
Average target price
285.9
USD
Spread / Average Target
+26.02%
- Stock Market
- Certificates
- Certificat
